Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial
Authors
Paz-Ares, LSpira, A
Raben, D
Planchard, D
Cho, BC
Ozguroglu, M
Daniel, D
Villegas, A
Vicente, D
Hui, R
Murakami, S
Spigel, D
Senan, S
Langer, CJ
Boothman, AM
Broadhurst, H
Wadsworth, C
Dennis, PA
Antonia, SJ
Faivre-Finn, Corinne
Affiliation
Hospital Universitario 12 de Octubre, Lung Cancer Unit CNIO-H12o, CiberOnc and Universidad Complutense, Madrid, SpainIssue Date
2020
Metadata
Show full item recordCitation
Paz-Ares L, Dziadziuszko R, Drilon A, John T, Krebs M, Demetri G, et al. Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors or ROS1-Positive NSCLC with CNS Metastases. Oncology Research and Treatment. 2020;43:235-Journal
Annals of OncologyDOI
10.1016/j.annonc.2020.03.287PubMed ID
32209338Additional Links
https://dx.doi.org/10.1016/j.annonc.2020.03.287Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2020.03.287
Scopus Count
Collections
Related articles
- Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
- Authors: Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ
- Issue date: 2021 Jan
- Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
- Authors: Socinski MA, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Gray JE, Park K, Vincent M, Mann H, Newton M, Dennis PA, Antonia SJ
- Issue date: 2021 Nov
- Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
- Authors: Senan S, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Murakami S, Hui R, Faivre-Finn C, Paz-Ares L, Wu YL, Mann H, Dennis PA, Antonia SJ
- Issue date: 2022 Apr
- Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
- Authors: Nindra U, Shahnam A, Stevens S, Pal A, Nagrial A, Lee J, Yip PY, Adam T, Boyer M, Kao S, Bray V
- Issue date: 2024 Feb
- Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
- Authors: Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray JE, Özgüroğlu M, Lee KH, Cho BC, Kato T, de Wit M, Newton M, Wang L, Thiyagarajah P, Antonia SJ
- Issue date: 2021 May